Exhibit 4.4


 


WARRANT


 


THIS WARRANT AND THE SHARES ISSUABLE UPON
EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
LAWS, OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY TO THE ISSUER THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT
OR APPLICABLE STATE SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.


 





 



 




Warrant To Purchase Common Stock


 


	Warrant No.:  6	Number of Shares:  30,000
	 	Warrant Exercise Price:  $4.96 per share
	Issuance Date:  January 1, 2020	Expiration Date:  January 2, 2027


 


Inhibikase
Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that Francis E. McDaniel (the
 “Holder”), the registered Holder hereof or its permitted assigns, is entitled, subject to the terms set forth
below, to purchase from the Company upon surrender of this Warrant, at any time or times on or after the date hereof (the “Effective
Date”), but not after 11:59 P.M. Eastern Time on the Expiration Date (as defined herein), Thirty Thousand (30,000) fully
paid and nonassessable shares of Common Stock (as defined herein) of the Company (the “Warrant Shares”) at
the exercise price per share of Four Dollars and Ninety Six Cents ($4.96). Upon the written request of the Holder, the Company
shall promptly, but in no event later than three (3) Business Days following the receipt of such notice, confirm in writing to
any such Holder the number of shares of Common Stock available to purchase from the Company upon surrender of this Warrant. The
Holder and the Company agree that notwithstanding any terms to the contrary contained herein, the Holder shall have no right to
exercise this Warrant until the Effective Date.


 


Section 1.            
Definitions


 


(a)         
The following words and terms as used in this Warrant shall have the following meanings:


 


(i)              
“Affiliated Entity” means any general partner of a Person, if such Person is a partnership, or any person
or entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or in under common control
with, such Person.


 


(ii)             
“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in New
York City or the State of New York are authorized or required by law to remain closed.


 






     



     


    

 





(iii)            
 “Common Stock” means (i) the Company’s Common Stock, par value $0,001 per share, and (ii) any
capital stock into which such Common Stock shall have been changed or any capital stock resulting from a reclassification of such
Common Stock.


 


(iv)            
“Effective Date” means the January 1, 2020.


 


(v)             
“Expiration Date” means January 2, 2027.


 


(vi)            
“Issuance Date” means January 1, 2020.


 


(vii)          
“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization and a government or any department or agency thereof.


 


(viii)          
“Registration” means consummation of the Company’s sale of its


 


Common Stock or other capital stock pursuant
to a registration statement which is declared effective in accordance with the Securities Act (other than a registration statement
relating either to sale of securities to employees of the Company pursuant to its stock option, stock purchase or similar plan
or a SEC Rule 145 transaction).


 


(ix)            
“Registration Expenses” means all fees and expenses incident to the Company’s performance of or
compliance with Section 4 of this Warrant, including, without limitation, (i) all registration and filing fees (including, without
limitation, (A) fees with respect to filings required to be made with FINRA in connection with an underwritten offering, (B) fees
and expenses of compliance with state securities or “blue sky” laws, and (C) transfer taxes); (ii) printing, messenger,
telephone and delivery expenses; (iii) fees and disbursements of counsel for the Company; (iv) fees and disbursements of all independent
certified public accountants retained by the Company; (v) underwriters’ fees and expenses (excluding discounts, commissions,
or fees of underwriters, selling brokers, dealer managers or similar securities industry professionals relating to the distribution
of the Warrant Shares); (vi) Securities Act liability insurance, if the Company so desires such insurance; (vii) internal expenses
of the Company; (viii) the expense of any annual audit; (ix) the fees and expenses incurred in connection with the listing of the
securities to be registered on any securities exchange; and (x) the fees and expenses of any Person, including special experts,
retained by the Company.


 


(x)             
“Securities Act” means the Securities Act of 1933, as amended.


 


(xi)            
“Warrant” means this Warrant and all Warrants issued in exchange, transfer or replacement thereof.


 


(xii)           
“Warrant Exercise Price” shall be the price set forth on page one of this Warrant or as subsequently
adjusted as provided in Section 8 hereof.


 


(b)        
Other Definitional Provisions.


 


(i)               Except
as otherwise specified herein, all references herein (A) to the Company shall be deemed to include the Company’s
successors and (B) to any applicable law defined or referred to herein shall be deemed references to such applicable law as
the same may have been or may be amended or supplemented from time to time.


 






    -2- 



     


    

 


(ii)             
When used in this Warrant, the words “herein”, “hereof’, and “hereunder”
and words of similar import, shall refer to this Warrant as a whole and not to any provision of this Warrant, and the words “Section”,
 “Schedule”, and “Exhibit” shall refer to Sections of, and Schedules and Exhibits to, this
Warrant unless otherwise specified.


 


(iii)            
Whenever the context so requires, the neuter gender includes the


 


masculine or feminine, and the singular
number includes the plural, and vice versa.


 


Section 2.            
Exercisability of Warrant.


 


(a)         
The number of shares of Common Stock issuable pursuant to this Warrant are fully vested.


 


Section 3.            
Exercise of Warrant.


 


(a)         Subject
to the terms and conditions hereof, this Warrant may be exercised by the Holder hereof then registered on the books of the
Company, in whole or in part, at any time on any Business Day on or after the opening of business on such Business Day,
commencing with the Effective Date, and prior to 11:59 P.M. Eastern Time on the Expiration Date, by (i) delivery of a written
notice, in the form of the subscription notice attached as Exhibit A hereto (the “Exercise
Notice”), of such Holder’s election to exercise this Warrant, which notice shall specify the number of
Warrant Shares to be purchased which shall not be less than 1,000 shares in each case (or if less than 1,000 shares are
available to purchase from the Company pursuant to this Warrant), such lesser amount (as such minimum number may be adjusted
pursuant to Section 8), (ii) payment to the Company of an amount equal to the Warrant Exercise Price(s) applicable to the
Warrant Shares being purchased, multiplied by the number of Warrant Shares (at the applicable Warrant Exercise Price) as to
which this Warrant is being exercised (plus any applicable issue or transfer taxes) (the “Aggregate Exercise
Price”) in cash or wire transfer of immediately available funds and (iii) the surrender of this Warrant (or an
indemnification undertaking with respect to this Warrant in the case of its loss, theft or destruction) to a common carrier
for overnight delivery to the Company as soon as practicable following such date. Upon delivery of the Exercise Notice and
Aggregate Exercise Price referred to in clause (ii) above the Holder of this Warrant shall be deemed for all corporate
purposes to have become the Holder of record of the Warrant Shares with respect to which this Warrant has been exercised.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the
Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in
full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) trading days of
the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The
Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for
purchase hereunder at any given time may be less than the amount stated on the face hereof.


 






    -3- 



     


    

 


(b)        
The Company shall use best efforts to cause the Warrant Shares purchased hereunder to be transmitted by its transfer agent
to the Holder by crediting the account of the Holder’s broker with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (“DWAC”) if the Company is then a participant in such system if there is an effective registration
statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder, and otherwise by physical
delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the
number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the
Notice of Exercise by the time and date that is no later than 11:00 am, Eastern time, on the tenth (10th) trading day after the
latest of (A) the delivery to the Company of the Notice of Exercise, (B) surrender of this Warrant (if required) and (C) payment
of the Aggregate Exercise Price (such date, the “Warrant Share Delivery Date”). In no event may the Warrants
be settled in cash. If there is no effective registration statement permitting the resale of the Warrant Shares, then any Warrant
Shares delivered upon exercise of this Warrant shall be restricted shares. The Company has no obligation of any kind to register
the Warrant Shares for resale. The Warrant Shares shall be deemed to have been issued, and the Holder or any other person so designated
to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant
has been exercised, with payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any,
pursuant to Section 3(e) prior to the issuance of such shares, having been paid.


 


(c)        
Unless the rights represented by this Warrant shall have expired or shall have been fully exercised, the Company shall,
as soon as practicable and in no event later than thirty (30) Business Days after any exercise and at its own expense, upon written
request of the Holder issue a new Warrant identical in all respects to this Warrant exercised except it shall represent rights
to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant exercised, less the
number of Warrant Shares with respect to which such Warrant is exercised.


 


(d)        
No fractional Warrant Shares are to be issued upon any exercise of this Warrant, but rather the number of Warrant Shares
issued upon such exercise of this Warrant shall be rounded up or down to the nearest whole number.


 


(e)        
Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such
Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that, in the event Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Warrant Power in the form attached hereto as Exhibit B duly executed by the Holder,
and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
thereto.


 






    -4- 



     


    

 





(f)         
 If at any time the Company proposes to merge or consolidate with or into any other corporation, effect any reorganization,
or sell or convey all or substantially all of its assets to any other entity, then, as a condition of such reorganization, consolidation,
merger, sale or conveyance, the Company or its successor, as the case may be, shall enter into a supplemental agreement to make
lawful and adequate provision whereby the Holder shall have the right to receive, upon exercise of this Warrant, the kind and amount
of equity securities which would have been received upon such reorganization, consolidation, merger, sale or conveyance by a Holder
of a number of shares of Common Stock equal to the number of shares issuable upon exercise of this Warrant immediately prior to
such reorganization, consolidation, merger, sale, or conveyance. The Company shall give the Holder of this Warrant ten (10) Business
Days’ prior written notice of the proposed effective date of any such merger, consolidation, reorganization, sale or conveyance,
and the Company shall also give the Holder of this Warrant ten (10) Business Days’ prior written notice of the commencement
of the Company’s voluntary or involuntary dissolution, liquidation or winding up. If the property to be received upon such
merger, consolidation, reorganization, sale or conveyance is not equity securities, and if this Warrant has not been exercised
by or on the effective date of such transaction, it shall terminate.


 


(g)        
If, at any time while this Warrant is outstanding, the Company declares or makes any dividend or other distribution of its
assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), then, in each
such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant immediately
before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record
holders of shares of Common Stock arc to be determined for the participation in such Distribution.


 


Section 4.            
Covenants as to Common Stock. The Company hereby covenants and agrees as follows:


 


(a)         
This Warrant is duly authorized and validly issued.


 


(b)        
All Warrant Shares which may be issued upon the exercise of the rights represented by this Warrant will, upon issuance,
be validly issued, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issue thereof.


 


(c)         
The Company will at all times have authorized and reserved at least one hundred percent (100%) of the number of shares of
Common Stock needed to provide for the exercise of the rights then represented by this Warrant and the par value of said shares
will at all times be less than or equal to the applicable Warrant Exercise Price.


 


(d)         The
Company will not, by amendment of its Articles of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms to be observed or performed by it hereunder, but will at all times in good
faith assist in the carrying out of all the provisions of this Warrant.


 






    -5- 



     


    

 


Section 5.            
Warrant Holder Not Deemed a Stockholder. Except as otherwise specifically provided herein, no Holder, as such, of
this Warrant shall be entitled to vote or receive dividends or be deemed the holder of shares of capital stock of the Company for
any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder hereof, as such, any of the rights
of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization,
issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive
dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which Holder is then
entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as
imposing any liabilities on such Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder
of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.


 


Section 6.            
Representations of Holder. The Holder of this Warrant, by the acceptance hereof, represents that it is acquiring
this Warrant and the Warrant Shares for its own account for investment only and not with a view towards, or for resale in connection
with, the public sale or distribution of this Warrant or the Warrant Shares, except pursuant to sales registered or exempted under
the Securities Act; provided, however, that by making the representations herein, the Holder does not agree to hold this Warrant
or any of the Warrant Shares for any minimum or other specific term and reserves the right to dispose of this Warrant and the Warrant
Shares at any time in accordance with or pursuant to a registration statement or an exemption under the Securities Act and other
applicable securities laws. The Holder of this Warrant further represents, by acceptance hereof, that, as of this date, such Holder
is an “accredited investor” as such term is defined in Rule 501(a)(1) of Regulation D promulgated by the Securities
and Exchange Commission under the Securities Act (an “Accredited Investor”). Upon exercise of this Warrant the
Holder shall, if requested by the Company, confirm in writing, in a form satisfactory to the Company, that the Warrant Shares so
purchased are being acquired solely for the Holder’s own account and not as a nominee for any other party, for investment,
and not with a view toward distribution or resale and that such Holder is an Accredited Investor. If such Holder cannot make such
representations because they would be factually incorrect, it shall be a condition to such Holder’s exercise of this Warrant
that the Company receive such other representations as the Company considers reasonably necessary to assure the Company that the
issuance of its securities upon exercise of this Warrant shall not violate any United States or state securities laws.


 


Section 7.            
Ownership and Transfer.


 


(a)         
The Company shall maintain at its principal executive offices (or such other office or agency of the Company as it may designate
by notice to the Holder hereof), a register for this Warrant, in which the Company shall record the name and address of the person
or entity in whose name this Warrant has been issued, as well as the name and address of each transferee. The Company may treat
the person in whose name any Warrant is registered on the register as the owner and Holder thereof for all purposes, notwithstanding
any notice to the contrary, but in all events recognizing any transfers made in accordance with the terms of this Warrant.


 






    -6- 



     


    

 





(b)        
 The Company agrees that, subject to the satisfaction of the conditions set forth in this Section 7(b), the Holder shall
be entitled to transfer all or any portion of this Warrant or of the Warrant Shares (i) in the case that the Holder is an incorporated
or other entity, to an Affiliated Entity of the Holder or (ii) in the case that the Holder is a natural person, for bona fide estate
planning purposes, either during his or her lifetime or on death by will or intestacy to his or her spouse, child (natural or adopted),
or any other direct lineal descendant of such Holder (or his or her spouse) (all of the foregoing collectively referred to as “family
members”), or to any custodian or trustee of any trust, partnership or limited liability company for the benefit of, or the
ownership interests of which are owned wholly by, such Holder or any such family members. The Holder agrees not to make any transfer
or disposition of the Warrant or all or any portion of the Warrant Shares to any Affiliated Entity, family member or custodian
or trustee or to any other Person unless and until (i) the Holder shall have notified the Company of the proposed disposition and
shall have furnished the Company with a reasonably detailed statement of the circumstances surrounding the proposed disposition
and (ii) the transferee has agreed in writing for the benefit of the Company to be bound by the terms of this Warrant and any other
stockholder or similar agreement among substantially all other holders of Common Stock as reasonably requested by the Company.
Any transfer in violation of this Section 7(b) shall be void ab initio.


 


Section 8.           
Adjustment of Warrant Exercise Price and Number of Shares. The Warrant Exercise Price and the number of shares of
Common Stock issuable upon exercise of this Warrant shall be adjusted from time to time as follows:


 


(a)        
Adjustment of Warrant Exercise Price upon Subdivision or Combination of Common Stock. If the Company at any
time after the date of issuance of this Warrant subdivides (by any stock split, stock dividend, recapitalization or otherwise)
one or more classes of its outstanding shares of Common Stock into a greater number of shares, any Warrant Exercise Price in effect
immediately prior to such subdivision will be proportionately reduced and the number of shares of Common Stock obtainable upon
exercise of this Warrant will be proportionately increased. If the Company at any time after the date of issuance of this Warrant
combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into
a smaller number of shares, any Warrant Exercise Price in effect immediately prior to such combination will be proportionately
increased and the number of Warrant Shares issuable upon exercise of this Warrant will be proportionately decreased. Any adjustment
under this Section 8(a) shall become effective at the close of business on the date the subdivision or combination becomes effective.


 


(b)        
Notices. Promptly upon any adjustment of the Warrant Exercise Price, the Company will give written notice thereof
to the Holder of this Warrant, setting forth in reasonable detail, and certifying, the calculation of such adjustment.


 


Section 9.           
Mutilated or Destroyed Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company shall promptly,
on receipt of an indemnification undertaking (or, in the case of a mutilated Warrant, the Warrant), issue a new Warrant of like
denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.


 


Section 10.          Notice.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Warrant must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when
sent by facsimile (provided confirmation of receipt is received by the sending party transmission is mechanically or
electronically generated and kept on file by the sending party); or (iii) one Business Day after deposit with a nationally
recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses and
facsimile numbers for such communications shall be:


 






    -7- 



     


    

 


	If to Holder:	Francis E. McDaniel

PO Box 681235

Marietta, Georgia 30067
	 	 
	If to the Company, to:	Inhibikase Therapeutics, Inc.

3350 Riverwood Parkway,

Suite 1900

Atlanta, GA 30339

Attn:  Milton Werner, Ph.D.

President and CEO


 


Each party shall provide five days’
prior written notice to the other party of any change in address or facsimile number. Written confirmation of receipt (A) given
by the recipient of such notice, consent, facsimile, waiver or other communication, or (B) provided by a nationally recognized
overnight delivery service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally
recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.


 


Section 11.          
Date. The date of this Warrant is set forth on page 1 hereof. This Warrant, in all events, shall be wholly void and
of no effect after the close of business on the Expiration Date.


 


Section 12.          
Amendment and Waiver. Except as otherwise provided herein, the provisions of the Warrants may be amended by a writing
executed by both the Company and the Holder.


 


Section 13.           Descriptive
Headings; Governing Law. The descriptive headings of the several sections and paragraphs of this Warrant are inserted for
convenience only and do not constitute a part of this Warrant. All questions concerning the construction, validity,
enforcement and interpretation of this Warrant shall be governed by the internal laws of the State of Delaware, without
giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other
jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Delaware. Each party
hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in Delaware, for the
adjudication of any dispute hereunder or in connection herewith or therewith, or with any transaction contemplated hereby or
discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an
inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy
thereof to such party at the address for such notices to it under this Warrant and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any
right to serve process in any manner permitted by law.


 






    -8- 



     


    

 


Section 14.         
Waiver of Jury Trial. AS A MATERIAL INDUCEMENT FOR EACH PARTY HERETO TO ENTER INTO THIS WARRANT, THE PARTIES HERETO
HEREBY WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING RELATED IN ANY WAY TO THIS WARRANT AND/OR ANY AND ALL OF THE OTHER
DOCUMENTS ASSOCIATED WITH THIS TRANSACTION.


 


Section 15.         
Lock-Up Agreement. If requested by the Company and the representative underwriter, Holder agrees to enter into a
lock-up agreement (the “Lock-Up Agreement”) pursuant to which it will not, for a period of no more than 180
days following the effective date of the first registration statement of the Company’s initial public offering, offer, sell
or otherwise dispose of the Warrant Shares or any other equity securities of the Company held. The Lock-up Agreement shall provide
that the provisions thereof may be waived with the consent of the Company and the representative underwriter.


 


IN WITNESS WHEREOF,
the Company has caused this Warrant to be signed as of the date first set forth above.


 


	 	 	COMPANY
	 	 	 
	HOLDER	 	Inhibikase Therapeutics, Inc.
	 	 	 
	By:	/s/ Francis E. McDaniel	 	By:	/s/ Milton Werner
	Name: 	Francis E. McDaniel	 	Name: 	Milton Werner, Ph.D.
	 	 	Title:	President & Chief Executive Officer



 






    -9- 



     


    

 


EXHIBIT
A TO WARRANT


 


EXERCISE
NOTICE


 


TO BE EXECUTED



BY THE REGISTERED HOLDER TO EXERCISE THIS WARRANT




 





 



 


The undersigned Holder
hereby exercises the right to purchase __________ shares of Common Stock (“Warrant Shares”) of Inhibikase Therapeutics,
Inc., a Delaware corporation (the “Company”), evidenced by the attached Warrant (the “Warrant”).
Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.


 


1.       Payment
of Warrant Exercise Price. The Holder shall pay the sum of $__________ to the Company in accordance with the terms of the Warrant.


 


2.       Delivery
of Warrant Shares. The Company shall deliver to the Holder $__________ Warrant Shares in accordance with the terms of the Warrant
and will issue said Warrant Shares in the name of the undersigned or in such other name or names as is specified below:


 


The Warrant Shares
shall be delivered to the following DWAC Account Number:


 


	[SIGNATURE
    OF HOLDER:]	 	 
	 	 	 
	Name
    of Holder:	 	 
	 	 	 
	Signature
    of Authorized Signatory:	 	 
	 	 	 
	Name
    of Authorized Signatory:	 	 
	 	 	 
	Title
    of Authorized Signatory:	 	 
	 	 	 
	Date:	 	 




 






    A-1



     


    

 





EXHIBIT
B TO WARRANT


 


FORM
OF WARRANT POWER


 


FOR VALUE RECEIVED,
the undersigned does hereby assign and transfer to ____________________, Federal Identification No. __________, a warrant to
purchase __________ shares of the capital stock of Inhibikase Therapeutics, Inc., a Delaware corporation, represented by warrant
certificate no. _____, standing in the name of the undersigned on the books of said corporation. The undersigned does hereby irrevocably
constitute and appoint __________, attorney to transfer the warrants of said corporation, with full power of substitution in the
premises.


 


	Dated:	 	 	



 


	 	 	 	 
	 	 	By:	 
	 	 	Name: 	 
	 	 	Title:	 


 



    B-1